Healthcare, Pharma & Life Sciences

Cryovials Market to Hit $0.31B by 2031 on Cell Therapy Demand

Image
Cryovials Market to Hit $0.31B by 2031 on Cell Therapy Demand

Delray Beach, Fla. – September 17, 2026 -- The global cryovials market is projected to grow from $0.24 billion in 2026 to $0.31 billion by 2031, expanding at a compound annual growth rate of 5.5%, according to MarketsandMarkets.

Cell and gene therapy demand drives fastest-growing application segment

The cell and gene therapy segment is set to register the highest CAGR among applications at 8.0%, fueled by expanding commercialization of CAR-T cell therapies, stem cell treatments, and gene-modified therapies. These advanced therapies require secure cryogenic storage across collection, processing, manufacturing, transportation, and administration to preserve cell viability. Manufacturers scaling from clinical to commercial production are prioritizing sterile, barcoded cryovials with secure closure systems compatible with automated storage.

Esperovax Wins USPTO Nod for In Vivo Yeast Protein Platform

Image
Esperovax Wins USPTO Nod for In Vivo Yeast Protein Platform

Plymouth, Mich. – – September 17, 2026 -- Esperovax, Inc. has secured a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 18/038,673, covering its engineered yeast platform for producing therapeutic proteins directly inside the body.

USPTO clears patent covering in vivo yeast-based protein expression

The allowed application, titled "Yeast-Based Expression of Therapeutic Proteins In Vivo," protects technology that uses engineered yeast administered to patients to manufacture biologic proteins within the body itself, rather than requiring external production and repeated dosing of purified biologics.

Eli Lilly Closes Acquisition of AtaiBeckley, Gains Depression Drug BPL-003

Image
Eli Lilly Closes Acquisition of AtaiBeckley, Gains Depression Drug BPL-003

Indianapolis – September 17, 2026 -- Eli Lilly and Company (NYSE: LLY) has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions.

Deal adds BPL-003 to Lilly's neuroscience pipeline for treatment-resistant depression

The acquisition brings Lilly control of AtaiBeckley's lead investigational program, BPL-003, targeting patients with treatment-resistant depression who have not responded to multiple prior therapies. AtaiBeckley shareholders approved the transaction at a special meeting held ahead of closing.

UrgentIQ Raises $15M Series A to Build AI Operating System for Urgent Care

Image
UrgentIQ Raises $15M Series A to Build AI Operating System for Urgent Care

New York – September 17, 2026 -- UrgentIQ has secured a $15 million Series A growth investment from Five Elms Capital to expand its AI-native electronic medical record platform for urgent care centers.

Five Elms Capital backs UrgentIQ's push beyond EMR into full clinical-financial platform

The funding will accelerate UrgentIQ's roadmap into a unified system covering AI-powered documentation, automated coding, revenue cycle management, insurance verification, and checkout. Founder and CEO Nat Gibbs built the platform specifically for urgent care workflows, distinguishing it from legacy EMRs adapted from hospital or primary care settings.

iGan Partners' Portfolio Lands $70M BARDA Deal, 166% Revenue Growth

Image
iGan Partners' Portfolio Lands $70M BARDA Deal, 166% Revenue Growth

Toronto – September 17, 2026 -- iGan Partners, a Toronto-based venture capital firm focused on medical device, diagnostic, imaging, and digital health companies, disclosed a series of portfolio milestones, headlined by a development contract worth up to $70 million awarded to portfolio company Flosonics Medical.

Flosonics secures BARDA contract to extend ultrasound tech into trauma care

The contract, from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services, includes approximately $15 million in initial funding. It supports FloPredict, an AI-enabled software enhancement to Flosonics' FDA-cleared FloPatch device, expanding the real-time ultrasound technology into trauma care and mass casualty response applications.

Waters CEO Udit Batra to Speak at J.P. Morgan Conference Sept. 23

Milford, Mass. – September 17, 2026 -- Waters Corporation (NYSE: WAT) will have President and CEO Udit Batra, Ph.D., participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on Wednesday, September 17, 2026.

Batra to address investors at 7:00 AM Eastern Time session

The fireside chat is scheduled for 12:00 PM BST (GMT+1), equivalent to 7:00 AM Eastern Time, on September 17, 2026.

Live webcast will run through Waters Investor Relations site

Waters will stream the session live via the 'Events & Presentations' section of its Investor Relations website. A replay will remain accessible for 90 days following the event.

Eloxx Doses First Patients in Phase 2b Alport Syndrome Trial

Image
Eloxx Doses First Patients in Phase 2b Alport Syndrome Trial

Arlington, Mass. – – September 17, 2026 -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has dosed the first two patients in the EXACT Study, a Phase 2b trial evaluating its investigational drug exaluren in patients with nonsense mutation Alport syndrome (NMAS), a rare kidney disease with no FDA-approved therapy targeting its genetic cause.

Trial targets 24 patients with a 16-week placebo-controlled start

The global, randomized, delayed-start Phase 2b trial will enroll 24 patients carrying nonsense mutations in the COL4A3, COL4A4, or COL4A5 genes. The initial 16-week placebo-controlled portion measures the drug's effect on structural podocyte changes via foot process effacement, assessed through kidney biopsies in non-U.S. pediatric patients and all adult participants.

AFSP Advocates Press Congress on $549.6M Lifeline Funding Push

Image
AFSP Advocates Press Congress on $549.6M Lifeline Funding Push

Washington – September 17, 2026 -- Seventeen Volunteer Advocates from the American Foundation for Suicide Prevention (AFSP) will meet with members of Congress from September 16-18 to push for sustained federal funding and pending legislation on suicide prevention, arriving weeks after Congress passed the Youth Poisoning Protection Act (H.R. 1442/S. 289), which now awaits presidential signature.

Advocates from 14 states demand $549.6 million for the 988 Suicide & Crisis Lifeline

The delegation, sponsored for a second year by AFSP's Illinois chapter during National Suicide Prevention Month, is lobbying for robust funding of the 988 Lifeline at $549.6 million, a $38 million allocation for the CDC's Comprehensive Suicide Prevention Program (CSP), and $2.548 billion for the National Institute of Mental Health.

Acarix Study Shows Acoustic Sensor Rivals Blood Test for Heart Failure

Image
Acarix Study Shows Acoustic Sensor Rivals Blood Test for Heart Failure

Oklahoma City – September 17, 2026 -- Acarix AB announced that a peer-reviewed study published in PLOS Digital Health found its seismocardiography (SCG) technology can detect heart failure with diagnostic accuracy comparable to NT-proBNP, the current standard blood test, while producing significantly fewer false positives.

SCG algorithm matches blood test accuracy with far higher specificity

Researchers at Aalborg University Hospital, Aarhus University Hospital and Odense University Hospital enrolled 218 patients, including 198 referred by general practitioners for suspected heart failure and 20 with previously confirmed HFrEF. Using machine learning, the team built two SCG-based scores: an 'AnyHF-score' to flag heart failure of any type, and an 'HFrEF-score' targeting the more severe reduced-ejection-fraction form of the condition.

Elanco to Report Q3 2026 Earnings on November 6

Image
Elanco to Report Q3 2026 Earnings on November 6

Indianapolis – September 17, 2026 -- Elanco Animal Health Incorporated (NYSE: ELAN) will release its third quarter 2026 financial results on Friday, September 17, 2026.

Elanco schedules conference call for 8:00 a.m. ET on November 6

The company will host a conference call with investors and media at 8:00 a.m. eastern time on the day of the results, detailing quarterly performance. A live webcast link will be posted on Elanco's investor relations website, with a replay made available shortly after the call concludes.